Current Opinion in Pharmacology最新文献_第3页

The role of plant-derived compounds in anti-obesity drug discovery: A molecular perspective 植物源性化合物在抗肥胖药物发现中的作用：分子视角。

IF 4.2 3区医学

Current Opinion in Pharmacology Pub Date : 2026-02-01 Epub Date: 2025-11-28 DOI: 10.1016/j.coph.2025.102597

Vetriselvan Subramaniyan , Ram Narayanan Ravi , Sammra Maqsood , Sachin Kumar Singh , Vellapandian Chitra , Kamal Dua , Brian G. Oliver , Sivaraman Dhanasekaran , Gaurav Gupta , Thakur Gurjeet Singh

{"title":"The role of plant-derived compounds in anti-obesity drug discovery: A molecular perspective","authors":"Vetriselvan Subramaniyan , Ram Narayanan Ravi , Sammra Maqsood , Sachin Kumar Singh , Vellapandian Chitra , Kamal Dua , Brian G. Oliver , Sivaraman Dhanasekaran , Gaurav Gupta , Thakur Gurjeet Singh","doi":"10.1016/j.coph.2025.102597","DOIUrl":"10.1016/j.coph.2025.102597","url":null,"abstract":"<div><div>Obesity is a complex and multifaceted disease associated with metabolic diseases and severe health problems worldwide. There is an urgent need for novel therapeutic strategies since the currently available treatment options are often ineffective or cause adverse effects. Since they can modulate crucial biochemical pathways,phytochemicals, which are plant-derived compounds, provide a promising approach to the design of anti-obesity drugs. Such ways through which these substances work are preventing adipogenesis, regulating lipid metabolism, dropping inflammation, improving insulin sensitivity, and reestablishing energy balance. These are some of the main topics of this review. Numerous phytochemicals have emerged as auspicious agents targeting adipocytes, gut bacteria, and essential enzymes elaborate in metabolic pathways associated to obesity, such as polyphenols, flavonoids, and terpenes. Additional preclinical and clinical data testify to the rationality of these molecules toward their intended therapy aims. Prospects for incorporating phytochemicals into treatment plans for obesity are deliberated next, along with potential synergistic effects of plant bioactives and allegations for polyherbal formulations.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"86 ","pages":"Article 102597"},"PeriodicalIF":4.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145795744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond tumor necrosis factor and interleukin-12/23: The rise of interleukin-23 inhibitors in inflammatory bowel disease management 肿瘤坏死因子和白细胞介素-12/23：白细胞介素-23抑制剂在炎症性肠病治疗中的应用

IF 4.2 3区医学

Current Opinion in Pharmacology Pub Date : 2026-02-01 Epub Date: 2025-11-20 DOI: 10.1016/j.coph.2025.102583

Catarina Costa , Nurulamin M. Noor , Maria Manuela Estevinho

{"title":"Beyond tumor necrosis factor and interleukin-12/23: The rise of interleukin-23 inhibitors in inflammatory bowel disease management","authors":"Catarina Costa , Nurulamin M. Noor , Maria Manuela Estevinho","doi":"10.1016/j.coph.2025.102583","DOIUrl":"10.1016/j.coph.2025.102583","url":null,"abstract":"<div><div>Interleukin-23 (IL-23) has been identified as a key driver of chronic intestinal inflammation and treatment resistance, particularly in patients who have failed anti-<em>tumor necrosis factor (</em>TNF) therapy. Genetic studies and preclinical models have confirmed IL-23's pivotal role in promoting both innate and adaptive immune responses in the gut. This review examines the biology of IL-23 and the evidence supporting its targeting in inflammatory bowel disease (IBD). Clinical trials of IL-23p19 inhibitors–such as risankizumab, mirikizumab, and guselkumab–have shown promising results in patients with moderate-to-severe Crohn's disease and ulcerative colitis, with improvements in clinical and endoscopic outcomes and favorable safety profiles. Recent real-world data further support their effectiveness, including in treatment-experienced populations. With regulatory approvals expanding in both the United States and Europe, IL-23 inhibitors are now firmly established as a part of the IBD treatment landscape. Looking ahead, efforts are underway to identify biomarkers of response and to explore oral IL-23 inhibitors, with the goal of advancing more personalized and accessible care.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"86 ","pages":"Article 102583"},"PeriodicalIF":4.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145749071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ivermectin and non-parasitic disorders: An update 伊维菌素和非寄生虫疾病：最新进展。

IF 4.2 3区医学

Current Opinion in Pharmacology Pub Date : 2025-12-01 Epub Date: 2025-09-16 DOI: 10.1016/j.coph.2025.102574

Behdad Seyyedabadi , Shabnam Babataheri , Marziyeh Naseri , Ismail Laher , Hamid Soraya

{"title":"Ivermectin and non-parasitic disorders: An update","authors":"Behdad Seyyedabadi , Shabnam Babataheri , Marziyeh Naseri , Ismail Laher , Hamid Soraya","doi":"10.1016/j.coph.2025.102574","DOIUrl":"10.1016/j.coph.2025.102574","url":null,"abstract":"<div><div>Ivermectin, a broad-spectrum anti-parasitic agent, demonstrates potential therapeutic benefits in treating non-parasitic ailments, particularly in neurological, respiratory, inflammatory, dermal, cardiovascular, and neoplastic disorders. For instance, ivermectin targets both DNA and RNA viruses, inhibits angiogenesis, and has anti-cancer properties, which result from inhibiting RNA helicase, inducing mitochondrial dysfunction, apoptosis, necrosis, and autophagy, as well as promoting oxidative stress. While the precise neurological impacts of ivermectin are not fully understood, it also has anticonvulsant properties in rats. Recent discoveries have revealed the neuroprotective effects of ivermectin in cerebral ischemia/reperfusion and Alzheimer's disease. Although there is limited research on the influence of ivermectin on the cardiovascular system, some studies have reported cardioprotective effects of ivermectin. However, a recent study suggested that ivermectin pre-treatment may have detrimental effects on myocardial ischemia. Consequently, numerous questions regarding the therapeutic/adverse effects of ivermectin remain unanswered and necessitate further investigation. We review the effects of ivermectin in non-parasitic diseases with an emphasis on current research in this field.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"85 ","pages":"Article 102574"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune cell subtype contributions to doxorubicin cardiotoxicity–defining immune targets for translational interventions 免疫细胞亚型对阿霉素心脏毒性的贡献——定义翻译干预的免疫靶点

IF 4.2 3区医学

Current Opinion in Pharmacology Pub Date : 2025-12-01 Epub Date: 2025-10-03 DOI: 10.1016/j.coph.2025.102581

Jens Van fraeyenhove, Giulia Guerra, Emilio Hirsch , Alessandra Ghigo

引用次数: 0

High-quality randomised controlled trials of acupuncture interventions for autism spectrum disorder in the last 10 years (2015–2024): A literature review 近10年来针灸干预自闭症谱系障碍的高质量随机对照试验（2015-2024）：文献综述

IF 4.2 3区医学

Current Opinion in Pharmacology Pub Date : 2025-12-01 Epub Date: 2025-09-26 DOI: 10.1016/j.coph.2025.102579

Zhengli Long , Jia Liu , Ruijie Sun

{"title":"High-quality randomised controlled trials of acupuncture interventions for autism spectrum disorder in the last 10 years (2015–2024): A literature review","authors":"Zhengli Long , Jia Liu , Ruijie Sun","doi":"10.1016/j.coph.2025.102579","DOIUrl":"10.1016/j.coph.2025.102579","url":null,"abstract":"<div><div>The efficacy of acupuncture as a nonpharmacological therapy for autism spectrum disorder (ASD) has been increasingly studied. To evaluate the current research methodologies and outcome measures in randomised controlled trials (RCTs) of acupuncture for ASD, we systematically searched eight major databases for relevant Chinese and English language literature published between 1 January 2015 and 31 December 2024. A total of 31 relevant studies were included in the literature review. Studies on acupuncture interventions for ASD were categorised into two- or three-arm designs, primarily employing indirect controls. Interventions predominantly utilised head acupoints for 12 weeks, and the acupuncture techniques were mainly tonifying and reducing techniques with moderate stimulation. Outcome indicators (n = 37) were categorised into six domains, selected a total of 111 times: symptoms and signs (59.46 %), physical and chemical test indicators (20.72 %), quality of life (8.11 %), safety events (7.21 %), functional status (2.70 %), and Chinese medical symptoms/syndrome (2.70 %). The Childhood Autism Rating Scale had the highest reporting rate among the indicators (23.24 %). Measurements were predominantly performed before treatment, post-treatment, and at the 12-week follow-up visit. Current evidence from RCTs on acupuncture for ASD is limited, restricting the clinical implementation of acupuncture protocols. Future high-quality studies should focus on standardising clinical trial designs, minimising bias, establishing consensus-driven outcome measurement selection, and developing a core outcome set for acupuncture in patients with ASD. These steps are essential for enhancing the methodological rigor and clinical relevance of acupuncture research in ASD.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"85 ","pages":"Article 102579"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145314021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Shaping surgical decisions in IBD — Unveiling the power of intestinal ultrasound across the perioperative pathway 影响IBD手术决策——揭示肠道超声在围手术期通路中的作用。

IF 4.2 3区医学

Current Opinion in Pharmacology Pub Date : 2025-12-01 Epub Date: 2025-09-23 DOI: 10.1016/j.coph.2025.102576

Hanne Theys , Elisabeth Eggermont , Simon Vancoillie , André D'Hoore , Gabriele Bislenghi , Bram Verstockt

{"title":"Shaping surgical decisions in IBD — Unveiling the power of intestinal ultrasound across the perioperative pathway","authors":"Hanne Theys , Elisabeth Eggermont , Simon Vancoillie , André D'Hoore , Gabriele Bislenghi , Bram Verstockt","doi":"10.1016/j.coph.2025.102576","DOIUrl":"10.1016/j.coph.2025.102576","url":null,"abstract":"<div><div>Intestinal ultrasound (IUS) is an increasingly utilized, non-invasive imaging modality in the management of inflammatory bowel disease (IBD). While its application in monitoring medical therapy is well recognized, its potential to support surgical decision-making remains underappreciated. This narrative review examines the role of IUS across the perioperative continuum in Crohn's disease (CD) and ulcerative colitis (UC), with a focus on practical surgical relevance.</div><div>In CD, IUS might contribute to the differentiation between inflammatory and fibrotic strictures, assessment of penetrating disease, and identification of real-time functional signs such as prestenotic dilation and swirling luminal contents. These findings guide early surgical referral and avoid unnecessary delays. Postoperatively, IUS allows for dynamic surveillance, with bowel wall thickness and Doppler flow serving as early markers of recurrence in CD. Assessments at 3, 6, and 12 months can guide therapeutic escalation or confirm remission without requiring invasive endoscopy. In acute severe UC, IUS can predict steroid non-response within 48 h and help define disease extent which might directly influences surgical strategy. Adjunct techniques such as contrast-enhanced ultrasound (CEUS), small intestinal contrast ultrasound (SICUS), and shear wave elastography (SWE) enhance diagnostic accuracy in specific settings. Moreover, muscle ultrasound provides a practical bedside tool to evaluate nutritional status and support preoperative risk stratification.</div><div>IUS offers surgeons a repeatable, accessible, and real-time diagnostic approach that bridges medical and surgical care. As evidence grows and standardization improves, IUS is poised to become a cornerstone in multidisciplinary IBD surgery, supporting precision, shared decision-making, and better outcomes.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"85 ","pages":"Article 102576"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145314064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CRISPR-Cas9 in acute myeloid leukaemia: Current state-of-art and future perspectives CRISPR-Cas9在急性髓性白血病中的应用：现状和未来展望

IF 4.2 3区医学

Current Opinion in Pharmacology Pub Date : 2025-12-01 Epub Date: 2025-10-16 DOI: 10.1016/j.coph.2025.102582

Federico Zingarelli , Jacopo Nanni , Gianluca Cristiano , Letizia Zannoni , Antonio Curti

引用次数: 0

Targeting the unmet needs in IBD: Emerging therapies beyond biologics and small molecules 针对IBD未满足的需求：生物制剂和小分子之外的新兴疗法。

IF 4.2 3区医学

Current Opinion in Pharmacology Pub Date : 2025-12-01 Epub Date: 2025-09-29 DOI: 10.1016/j.coph.2025.102577

Fabrizio Fanizzi , Laurent Peyrin-Biroulet , Silvio Danese , Ferdinando D'Amico

{"title":"Targeting the unmet needs in IBD: Emerging therapies beyond biologics and small molecules","authors":"Fabrizio Fanizzi , Laurent Peyrin-Biroulet , Silvio Danese , Ferdinando D'Amico","doi":"10.1016/j.coph.2025.102577","DOIUrl":"10.1016/j.coph.2025.102577","url":null,"abstract":"<div><div>Despite progress with biologics and small molecules, a substantial proportion of patients with inflammatory bowel disease (IBD) continue to face unmet needs, including non-response, disease recurrence, and impaired quality of life. These limitations highlight the need for novel therapeutic strategies that go beyond current pharmacological approaches, including biologics and small molecules. This review explores emerging therapies aimed at restoring immune balance, repairing intestinal function and improving long-term outcomes in IBD. Cellular and genetic therapies offer promising avenues to restore immune tolerance and promote mucosal healing in IBD. Likewise, microbiome-based interventions aim to rebalance gut inflammation and host–microbe interactions. Additional strategies focus on targeted immunomodulation through therapeutic peptides, RNA-based agents, and vaccines directed against intestinal antigens. Complementary and alternative medicine, including dietary approaches, nutraceuticals and psychological therapies is also gaining attention within integrative care models. While these approaches are conceptually compelling, most remain in the early stages of clinical or preclinical development. Their therapeutic potential has yet to be fully validated and further research is essential to establish their efficacy, safety, and long-term impact. Taken together, these emerging strategies represent a shift beyond conventional therapies, moving toward modifying disease trajectory and improving patient-centered outcomes. However, their successful integration into IBD clinical practice will require robust evidence, standardized protocols, and a multidisciplinary framework grounded in real-world applicability.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"85 ","pages":"Article 102577"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145349692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Revolutionizing Crohn's disease monitoring: The emerging role of intestinal ultrasound 革命性的克罗恩病监测：肠道超声的新兴作用。

IF 4.2 3区医学

Current Opinion in Pharmacology Pub Date : 2025-12-01 Epub Date: 2025-10-04 DOI: 10.1016/j.coph.2025.102580

Cristina Bezzio , Luisa Bertin , Arianna Dal Buono , Giuseppe Privitera , Roberto Gabbiadini , Laura Loy , Alessandro Armuzzi

{"title":"Revolutionizing Crohn's disease monitoring: The emerging role of intestinal ultrasound","authors":"Cristina Bezzio , Luisa Bertin , Arianna Dal Buono , Giuseppe Privitera , Roberto Gabbiadini , Laura Loy , Alessandro Armuzzi","doi":"10.1016/j.coph.2025.102580","DOIUrl":"10.1016/j.coph.2025.102580","url":null,"abstract":"<div><div>Intestinal ultrasound (IUS) is increasingly recognized as a valuable tool in the monitoring of Crohn's disease (CD), offering a non-invasive, real-time assessment of transmural inflammation. Unlike conventional endpoints based on clinical scores, biomarkers, or mucosal evaluation, IUS allows direct visualization of bowel wall changes, enabling earlier detection of treatment response and more accurate prognostic assessment. IUS has demonstrated good diagnostic performance for the detection of strictures, penetrating complications, and postoperative recurrence. The development of advanced modalities such as contrast-enhanced ultrasound (CEUS) and elastography has further expanded its potential, particularly in differentiating inflammatory from fibrotic lesions—an emerging clinical need in the context of anti-fibrotic therapies. Evidence suggests that IUS findings can influence therapeutic decisions in routine practice, supporting treatment escalation, de-escalation, or switching in a timely and objective manner. Special applications, including transperineal ultrasound and use during pregnancy, reinforce the versatility and safety of IUS in challenging clinical scenarios. While technical limitations persist in certain patient subgroups, IUS remains a repeatable, accessible, and well-tolerated imaging modality that complements other diagnostic tools. As artificial intelligence enhances image interpretation and quantitative analysis, IUS is poised to become a cornerstone of precision medicine in CD. Its capacity to guide timely, individualized decisions makes it an essential component of modern disease monitoring and treatment optimization strategies.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"85 ","pages":"Article 102580"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145402770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Revolutionizing UC monitoring: The emerging role of intestinal ultrasound 革命性UC监测：肠道超声的新作用。

IF 4.2 3区医学

Current Opinion in Pharmacology Pub Date : 2025-12-01 Epub Date: 2025-09-27 DOI: 10.1016/j.coph.2025.102578

Fabrizio Fanizzi , Alessandra Zilli , Ferdinando D'Amico , Silvio Danese , Mariangela Allocca

{"title":"Revolutionizing UC monitoring: The emerging role of intestinal ultrasound","authors":"Fabrizio Fanizzi , Alessandra Zilli , Ferdinando D'Amico , Silvio Danese , Mariangela Allocca","doi":"10.1016/j.coph.2025.102578","DOIUrl":"10.1016/j.coph.2025.102578","url":null,"abstract":"<div><div>Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by alternating periods of disease flare and remission, necessitating precise monitoring to guide therapeutic decisions. Traditionally, endoscopy has served as the cornerstone of disease assessment. However, its invasiveness, cost and limited accessibility have underscored the need for alternative approaches. Intestinal ultrasound (IUS) has emerged as a valuable, non-invasive tool capable of providing real-time information about intestinal inflammation at the bedside. This review explores the evolving role of IUS in UC monitoring and management, highlighting its utility in diagnosing disease activity, guiding therapeutic decisions, and supporting treat-to-target strategies. Despite current challenges such as operator dependency and variability in technique, growing evidence supports the incorporation of IUS into routine clinical practice, with ultrasound parameters being integrated into validated and predictive scoring systems to enhance disease monitoring and guide treatment decisions. By offering a safe, reproducible, and patient-friendly modality, IUS represents a significant advancement in the proactive management of UC, promising improved outcomes and greater quality of care.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"85 ","pages":"Article 102578"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145356746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0